The emerging science of precision medicine and pharmacogenomics for Parkinson's disease

Caffeine, creatine, GRIN2A and Parkinson's disease progression

(2017) David K. Simon et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease

(2017) Alastair J. Noyce et al.   MOVEMENT DISORDERS

Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials

(2017) Alberto J. Espay et al.   MOVEMENT DISORDERS

Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome

(2017) Erin M. Hill-Burns et al.   MOVEMENT DISORDERS

Gut microbiota modulation of chemotherapy efficacy and toxicity

(2017) James L. Alexander et al.   Nature Reviews Gastroenterology & Hepatology

Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease

(2017) Amy R. Dunn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A grim budget day for U.S. science: analysis and reaction to Trump's plan

(2017) Science Staff   SCIENCE

Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study

(2016) Mario Masellis et al.   BRAIN

Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease

(2016) Timothy R. Sampson et al.   CELL

The genetics of drug efficacy: opportunities and challenges

(2016) Matthew R. Nelson et al.   NATURE REVIEWS GENETICS

Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls

(2016) Marcus M. Unger et al.   PARKINSONISM & RELATED DISORDERS

Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease

(2016) Vivian Altmann et al.   PHARMACOGENOMICS

Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity

(2016) Alexandra Zhernakova et al.   SCIENCE

Population-level analysis of gut microbiome variation

(2016) Gwen Falony et al.   SCIENCE

Emerging Technologies for Gut Microbiome Research

(2016) Jason W. Arnold et al.   TRENDS IN MICROBIOLOGY

Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson’s disease

(2015) Caroline Moreau et al.   BRAIN

Caffeine and Progression of Parkinson Disease

(2015) David K. Simon et al.   CLINICAL NEUROPHARMACOLOGY

Colonic bacterial composition in Parkinson's disease

(2015) Ali Keshavarzian et al.   MOVEMENT DISORDERS

Pharmacogenomics in the clinic

(2015) Mary V. Relling et al.   NATURE

A New Initiative on Precision Medicine

(2015) Francis S. Collins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intestinal Dysbiosis and Lowered Serum Lipopolysaccharide-Binding Protein in Parkinson’s Disease

(2015) Satoru Hasegawa et al.   PLoS One

Individualized Medicine from Prewomb to Tomb

(2014) Eric J. Topol   CELL

Adenosine Receptors: Expression, Function and Regulation

(2014) Sandeep Sheth et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Gut microbiota are related to Parkinson's disease and clinical phenotype

(2014) Filip Scheperjans et al.   MOVEMENT DISORDERS

The ongoing pursuit of neuroprotective therapies in Parkinson disease

(2014) Dilan Athauda et al.   Nature Reviews Neurology

Parkinson's disease pharmacogenomics: new findings and perspectives

(2014) Artur F Schumacher-Schuh et al.   PHARMACOGENOMICS

Glutamate Receptor Gene GRIN2A, Coffee, and Parkinson Disease

(2014) Taye H. Hamza et al.   PLoS Genetics

Global Analysis of DNA Methylation Variation in Adipose Tissue from Twins Reveals Links to Disease-Associated Variants in Distal Regulatory Elements

(2013) Elin Grundberg et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease

(2013) Jeffrey H. Kordower et al.   BRAIN

Xenobiotics Shape the Physiology and Gene Expression of the Active Human Gut Microbiome

(2013) Corinne Ferrier Maurice et al.   CELL

Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective

(2013) Marc Maliepaard et al.   NATURE REVIEWS DRUG DISCOVERY

Promise of Pharmacogenomics for Drug Discovery, Treatment and Prevention of Parkinson’s Disease. A Perspective

(2013) Haydeh Payami et al.   Neurotherapeutics

Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed

(2013) H. L. McLeod   SCIENCE

Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta

(2013) H. J. Haiser et al.   SCIENCE

Caffeine for treatment of Parkinson disease: A randomized controlled trial

(2012) R. B. Postuma et al.   NEUROLOGY

HLA and pharmacogenetics of drug hypersensitivity

(2012) Rebecca Pavlos et al.   PHARMACOGENOMICS

A genetic basis for the variable effect of smoking/nicotine on Parkinson’s disease

(2012) E M Hill-Burns et al.   PHARMACOGENOMICS JOURNAL

Is It Time for a Metagenomic Basis of Therapeutics?

(2012) H. J. Haiser et al.   SCIENCE

NMDA receptor genotypes associated with the vulnerability to develop dyskinesia

(2012) S A Ivanova et al.   Translational Psychiatry

Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study

(2011) Robert D. Altman et al.   MOVEMENT DISORDERS

The Parkinson Progression Marker Initiative (PPMI)

(2011) Kenneth Marek et al.   PROGRESS IN NEUROBIOLOGY

Reengineering Translational Science: The Time Is Right

(2011) F. S. Collins   Science Translational Medicine

Colonization-Induced Host-Gut Microbial Metabolic Interaction

(2011) S. P. Claus et al.   mBio

Genome-Wide Gene-Environment Study Identifies Glutamate Receptor Gene GRIN2A as a Parkinson's Disease Modifier Gene via Interaction with Coffee

(2011) Taye H. Hamza et al.   PLoS Genetics

Web-Based Genome-Wide Association Study Identifies Two Novel Loci and a Substantial Genetic Component for Parkinson's Disease

(2011) Chuong B. Do et al.   PLoS Genetics

Global patterns of genetic diversity and signals of natural selection for human ADME genes

(2010) Jing Li et al.   HUMAN MOLECULAR GENETICS

Start/stop signals emerge in nigrostriatal circuits during sequence learning

(2010) Xin Jin et al.   NATURE

A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury

(2010) Jonathan B Singer et al.   NATURE GENETICS

Glutamate, excitotoxicity, and programmed cell death in parkinson disease

(2009) W. Michael Caudle et al.   EXPERIMENTAL NEUROLOGY

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

(2009) Ann K Daly et al.   NATURE GENETICS

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

(2009) Vijayaprakash Suppiah et al.   NATURE GENETICS

Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

(2009) Yasuhito Tanaka et al.   NATURE GENETICS

HLA-B*5701 Screening for Hypersensitivity to Abacavir

(2008) Simon Mallal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dichotomous Dopaminergic Control of Striatal Synaptic Plasticity

(2008) W. Shen et al.   SCIENCE

Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk

(2007) Karen M. Powers et al.   MOVEMENT DISORDERS